Keep Factually independent
Whether you agree or disagree with our analysis, these conversations matter for democracy. We don't take money from political groups - even a $5 donation helps us keep it that way.
What is Memoblast and its origins?
Executive summary
Memoblast appears to be a recently created web property or product name with little established public history; the domain memoblast.co was registered about one month ago and holds a moderate trust score of 59/100 according to an online scanner [1]. The term “Memoblast” does not appear in major corporate profiles for Mesoblast Limited, an Australian regenerative‑medicine company founded in 2004, though Mesoblast develops mesenchymal‑lineage cell therapies and has product names such as Ryoncil and Rexlemestrocel‑L [2] [3].
1. What the available reporting actually documents: a new domain, not a company history
The clearest, direct reference to “Memoblast” in the material provided is an online domain-safety scan of memoblast.co, which reports the site was registered roughly one month prior to the scan, lists the registrar (NAMECHEAP INC), and assigns a moderate trust score (59/100) while warning that new domains typically “lack established reputation metrics” [1]. That source frames Memoblast primarily as a new web property rather than an established biotech product or firm [1].
2. Mesoblast: a well‑documented regenerative‑medicine company with similar naming
Mesoblast Limited is an Australian regenerative medicine company founded in 2004 and led by Silviu Itescu; it specializes in off‑the‑shelf, mesenchymal‑lineage cell therapies for inflammatory, cardiovascular and orthopedic indications [2] [3]. Mesoblast’s public materials list product candidates such as Ryoncil (remestemcel‑L) and Rexlemestrocel‑L and describe a roughly 1,000‑patent portfolio covering mesenchymal cell technologies [3] [4]. These clear facts about Mesoblast’s history and pipeline are documented on company and industry profiles [2] [3] [4].
3. Similar names can cause confusion; available sources do not link Memoblast to Mesoblast
Because “Memoblast” and “Mesoblast” are visually and phonetically similar, casual readers may conflate them. The documents provided do not, however, establish any corporate, product or legal connection between memoblast.co and Mesoblast Limited; the domain scan treats memoblast.co as a standalone, recently created site [1]. Available sources do not mention any official Mesoblast product or subsidiary named “Memoblast” (not found in current reporting).
4. What the domain scanner report implies about reliability and risk
The gridinsoft scan flags features typical of new domains: recent registration, absence of established complaints or reviews, and use of popular product names to draw traffic [1]. A moderate trust score (59/100) indicates caution: the scanner judged the site neither clearly malicious nor fully vetted. That assessment suggests users should verify claims on memoblast.co against established sources before acting on them [1].
5. Context on how Mesoblast presents its products and IP—what to expect if this were related
If a legitimate product related to mesenchymal‑lineage therapies were being announced, Mesoblast’s public materials typically describe specific candidates by name (e.g., Ryoncil, Rexlemestrocel‑L), their indications, trial stages, and patent coverage through 2040 [3] [4]. Mesoblast publicly emphasizes partnerships and regulatory milestones—evidence the company communicates major developments through formal investor and company pages [3] [5]. The absence of “Memoblast” from those channels in the supplied results is notable [3] [5].
6. How to proceed prudently: verification checklist
Given the limited coverage, verify any Memoblast claims by checking (a) Mesoblast’s official investor and company pages and product lists for matching names [3] [5], (b) regulatory filings or press releases for product approvals or trial entries (Mesoblast typically reports such milestones) [2] [3], and (c) independent domain‑reputation services or news outlets beyond the one domain scan. The provided materials show Mesoblast’s established history and IP but do not corroborate Memoblast as part of that record [2] [3] [1].
7. Competing viewpoints and limitations of available reporting
One viewpoint: memoblast.co could be a legitimate new venture or brand that has yet to build publicly indexed links; the domain scan does not declare it a scam, only a moderate trust score [1]. Opposing viewpoint: the newness, lack of independent corroboration, and use of a name similar to a known biotech could indicate opportunistic branding to capture search traffic [1]. Limitations: the search results here are narrow—company filings, news databases, and regulatory registries were not provided—so available sources do not confirm or refute the broader origins or claims about Memoblast beyond the domain scan and the established Mesoblast profile [1] [2] [3].
Conclusion: Based on the supplied reporting, “Memoblast” is documented only as a newly registered website with a moderate trust score [1]. Mesoblast is a distinct, long‑running regenerative‑medicine company founded in 2004 with an established product pipeline and extensive patent holdings [2] [3]. Available sources do not link the two [1] [2] [3].